THE MEN BEHIND WELLBEINGChapter One: Andrew Chancellor
From Banking to Biologics
How a career in finance and recruitment led to the leadership of a regenerative-medicine organisation
Throughout this investigation, I have repeatedly returned to one principle.
Before examining what an organisation claims, understand the people making those claims.
That principle led me first to Wellbeing International Foundation's Chairman, Max Lewinsohn.
Now it leads to the organisation's Chief Executive Officer.
Andrew Chancellor.
If you encountered Chancellor today without knowing his history, you might reasonably assume that the chief executive of an organisation involved in personalised biological medicine had spent much of his professional career within medicine, biomedical science or clinical research.
That assumption would be wrong.
According to Wellbeing International Foundation's own biography, Chancellor's professional career began not in medicine—
but in banking.
From Banking...
Wellbeing describes Chancellor as having more than thirty years of business experience.
His career began in international banking in South Africa and the United Kingdom.
Chancellor himself has said that he worked for Barclays in Johannesburg before later working in London.
There is nothing remarkable about that.
Banking provides experience in finance, business and commercial decision-making.
But it is important because it establishes the starting point of the career we are examining.
There is no medical school.
No clinical training.
No biomedical degree identified.
His journey into regenerative medicine came considerably later.
...To Recruitment
After banking, Chancellor moved into international recruitment.
Wellbeing says he subsequently ran search and selection businesses across:
London.
Paris.
Hong Kong.
Singapore.
Sydney.
Again, this demonstrates considerable international business experience.
Recruitment businesses require sales ability, management, negotiation and an understanding of people.
Those are useful skills for any chief executive.
But they are not medical qualifications.
And that distinction becomes increasingly important as the story develops.
Then Came Bioscience
According to Wellbeing, Chancellor eventually moved into healthcare and bioscience.
The organisation says that for approximately fifteen years he has worked in the sector, helping translate research into clinical practice.
But Chancellor's own account provides considerably more insight into how that transition occurred.
He says he met Stephen Ray—the scientist whose research sits behind Wellbeing's work.
Their conversations developed around the potential of the underlying biology.
Those discussions eventually turned toward something very different from academic research:
commercialisation.
How could the research be turned into something that could be delivered in clinical practice?
How could an organisation be constructed around it?
And how could that organisation operate commercially?
That appears to be the point at which Andrew Chancellor's business career and Stephen Ray's scientific work converged.
Learning the Science
Perhaps one of the most revealing descriptions of Chancellor's transition into regenerative medicine comes from Chancellor himself.
Asked about the challenges he faced entering the sector, he explained that one of the greatest was understanding the science and medicine sufficiently to lead responsibly.
His solution, he says, was extensive reading, questioning and research.
That deserves acknowledgement.
A chief executive running a biotechnology organisation should understand the science behind the company.
But it also establishes an important distinction.
Chancellor appears to describe his medical and scientific knowledge as something developed through self-directed study and experience within the sector, rather than through formal medical education.
I have found no qualification listed by Wellbeing identifying Chancellor as a medical doctor.
No medical school is listed.
No clinical specialty is identified.
No medical registration is presented in his company biography.
That does not prevent him from running a healthcare company.
Many successful healthcare executives are not doctors.
But it becomes important when considering exactly what role Chancellor plays when dealing with patients.
Wellbeing Makes the Distinction Itself
Interestingly, Wellbeing's own leadership structure appears to recognise these different areas of expertise.
Andrew Chancellor is identified as:
Chief Executive Officer.
His background is banking, recruitment and business.
Stephen Ray is separately identified as the organisation's senior scientific figure.
His background is scientific research.
And Dr Gerhard Boonstra is separately identified as Wellbeing's Senior Medical Consultant.
Wellbeing states that Boonstra obtained his medical degree from Stellenbosch University in 1993 before working as an emergency-room doctor and later a GP.
The organisation therefore appears to divide its leadership expertise into three distinct areas:
Chancellor — business.
Ray — science.
Boonstra — medicine.
On paper, that is entirely logical.
The question is whether those boundaries remain equally clear when prospective patients enter the process.
From Research to Treatment
Chancellor's role appears to have become increasingly important as the research moved toward commercial application.
In one recent interview, he describes himself as overseeing Wellbeing's commercial operations while supporting the development and delivery of regenerative biologics.
Another published article goes further.
It claims Chancellor worked alongside Stephen Ray in helping develop and refine protocols associated with Wellbeing's autologous extracellular-vesicle approach.
That statement deserves closer examination.
What precisely does "develop protocols" mean?
Commercial protocols?
Operational procedures?
Patient pathways?
Scientific protocols?
Clinical treatment protocols?
Those are very different things.
Before drawing conclusions, the original basis for that claim needs to be established.
The CEO Becomes a Public Authority
What is undeniable is that Chancellor has increasingly become one of Wellbeing's principal public voices.
He speaks about regenerative medicine.
He discusses biological treatments.
He discusses patients.
He discusses clinical outcomes.
He discusses the science.
And he discusses who Wellbeing believes may—or may not—benefit from its programme.
That last point is particularly important.
In one interview Chancellor explained that Wellbeing sometimes refuses patients where its data suggests they are unlikely to benefit.
On its face, that sounds responsible.
No healthcare business should sell an expensive intervention to someone it believes is unlikely to benefit.
But it creates another question.
Who makes that assessment?
Who Decides?
This may ultimately become one of the most important questions in the Chancellor investigation.
When a prospective patient approaches Wellbeing with a medical condition, somebody must determine whether that person is suitable.
Who reviews their medical history?
Who interprets their diagnosis?
Who examines their medications?
Who considers contraindications?
Who evaluates potential benefit?
Who determines whether Cell-Free Therapy is appropriate?
And who has final authority to say:
Yes, this patient qualifies.
If that decision is made by a registered physician, the clinical pathway should be straightforward to establish.
If Chancellor simply communicates a physician's decision, that is equally important context.
But if a commercially responsible chief executive without an identified medical qualification personally participates in determining whether an individual patient is clinically suitable for an expensive biological intervention, that raises a very different set of questions.
Those questions require evidence.
This Is Where My Investigation Changes
Until now, much of the Chancellor story could be reconstructed from biographies and interviews.
Banking.
Recruitment.
Meeting Stephen Ray.
Entering bioscience.
Building Wellbeing.
Commercialising the research.
But I also have evidence from the patient side of the organisation.
And that means the next stage of this investigation becomes considerably more important.
Because corporate biographies tell us what someone's job is supposed to be.
Patient interactions can tell us what they actually do.
A Question of Boundaries
There is nothing improper about a non-doctor running a medical company.
Hospitals have non-medical chief executives.
Pharmaceutical companies have non-medical executives.
Biotechnology companies frequently have CEOs from finance, law, engineering and business.
The relevant question is not:
Why isn't Andrew Chancellor a doctor?
The relevant question is:
Where does Andrew Chancellor's role stop and the doctor's role begin?
That boundary matters.
Commercial leadership is one thing.
Explaining a company's technology is another.
Discussing general scientific research is another.
But assessing an individual person's medical condition, determining suitability for treatment or predicting whether an intervention might benefit them enters substantially more sensitive territory.
Establishing exactly where Wellbeing draws that line is therefore essential.
What We Know
At this stage, the documented record establishes several things.
Andrew Chancellor began his professional career in banking.
He subsequently built businesses within international recruitment.
He later entered healthcare and bioscience after becoming involved with Stephen Ray and the research that eventually became central to Wellbeing.
He is now Chief Executive Officer of Wellbeing International Foundation.
Wellbeing does not publicly identify him as a medical doctor.
The organisation separately identifies a qualified physician as its senior medical consultant.
Chancellor nevertheless speaks publicly about Wellbeing's patient-selection process and says patients may be declined where the organisation's data suggests they will not benefit.
None of those facts independently establishes anything improper.
Together, however, they create a question that deserves an answer.
Who Is Actually Assessing the Patient?
That is where Chapter Two begins.
Because the next stage of this investigation moves away from corporate biographies and into the patient journey itself.
What happens when someone contacts Wellbeing with a serious medical condition?
Who speaks to them?
What questions are asked?
What claims are made?
When does a doctor become involved?
Who determines that the patient is suitable?
And at what point does a medical conversation become a £37,000 commercial proposition?
Those questions cannot be answered from a biography.
But they can be answered from evidence.
And that is exactly where this investigation goes next.
Comments